none 10.6061/clinics/2012(07)03 Elsevier BV Elsevier 78 56672266 45578 2025102811221600000 10.1016 2025-10-29T07:07:40Z 2012-07-23T10:17:54Z 17 Clinics Clinics 18075932 07 2012 67 7 Helena Atroch Machado Marcelo Vieira Maria Rosaria Cunha Marcia Regina Soares Correia Rosa Tsunechiro Fukui Rosa Ferreira dos Santos Dalva Marreiro Rocha Bernardo Leo Wajchenberg Silvia G. Lage Maria Elizabeth Rossi da Silva 07 2012 711 717 S1807593222017628 S1807593222017628 10.1016/elsevier_cm_policy elsevier.com sciencedirect.com true Elsevier Metformin, but not glimepiride, improves carotid artery diameter and blood flow in patients with type 2 diabetes mellitus Clinics https://doi.org/10.6061/clinics/2012(07)03 article Copyright © 2012 CLINICS. Published by Elsevier Spain https://www.elsevier.com/tdm/userlicense/1.0/ https://www.elsevier.com/legal/tdmrep-license https://creativecommons.org/licenses/by-nc/3.0/ 10.6061/clinics/2012(07)03 https://linkinghub.elsevier.com/retrieve/pii/S1807593222017628 http://clinics.org.br/uploads/artigos/cln-67-7/cln-67-07-711.pdf https://api.elsevier.com/content/article/PII:S1807593222017628?httpAccept=text/xml https://api.elsevier.com/content/article/PII:S1807593222017628?httpAccept=text/plain https://dul.usage.elsevier.com/doi/ http://www.scielo.br/scielo.php?script=sci_abstract&pid=S1807-59322012000700003&lng=en&nrm=iso http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400159/?report=classic Am J Med Stolar 123 Suppl. 3 S3 2010 10.1016/j.amjmed.2009.12.004 Glycemic control and complications in type 2 diabetes mellitus Diabetes Care 32 Suppl. 1 S13 2009 American Diabetes Association- Standards of medical care in diabetes Diabetes and Vascular Disease Research Scarpello 5 157 2008 10.3132/dvdr.2008.027 Metformin therapy and clinical uses Cardiovascular Drugs Ther Bailey 22 3 215 2008 10.1007/s10557-008-6092-0 Metformin: Effects on micro and macro vascular complications in type 2 diabetes Horm Metab Res Draeger 28 9 419 1996 10.1055/s-2007-979830 Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide Diabetes Obes Metab Mori 10 7 596 2008 10.1111/j.1463-1326.2008.00870.x Glimepiride as insulin sensitizer: increased liver and muscle responses to insulin Diabetes Res Clin Pract Sadikot 82 3 391 2008 10.1016/j.diabres.2008.09.004 Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study Diabetes Metab Res Rev Monami 22 6 477 2006 10.1002/dmrr.642 Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin Diabetologia Bijlstra 39 9 1083 1996 10.1007/BF00400658 Interaction of sulfonylurea derivate with vascular ATP-sensitive potassium channels in humans A double-blind, placebo controlled evaluation of glimepiride and glibenclamide. European Heart Journal Klepzig 20 6 439 1999 Sulfonylureas and ischemic preconditioning J Clin Endocrinol Metab Lee 88 2 531 2003 10.1210/jc.2002-020904 Impairment of myocardial protection in type 2 diabetic patients glimepiride and metformin in Type 2 diabetic patients. Diabet Med Abbink 19 2 136 2002 Vascular effects of glibenclamide vs Diabetes Care Spallarossa 24 4 738 2001 10.2337/diacare.24.4.738 Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia J Am Coll Cardiol Pfützner 45 12 1925 2005 10.1016/j.jacc.2005.03.041 Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study Effects of metformin and rosiglitazone. Med Princ Pract Yener 18 4 266 2009 10.1159/000215722 Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications Diabetes Metab Rizzo 31 3 Pt 1 255 2005 10.1016/S1262-3636(07)70192-1 Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study Diabetes Nutr Metab Derosa 17 143 2004 Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin Clin Ther Derosa 25 2 472 2003 10.1016/S0149-2918(03)80090-5 Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors Clin Ther Luis 25 1 194 2003 10.1016/S0149-2918(03)90025-7 Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study J Am Coll Cardiol Corretti 39 2 257 2002 10.1016/S0735-1097(01)01746-6 Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force Clin Chem Latt 21 12 1754 1975 10.1093/clinchem/21.12.1754 Evaluations of Trinder's glucose oxidase method for measuring glucose in serum and urine New Engl J Med Trivelli 284 353 1971 10.1056/NEJM197102182840703 Hemoglobin components in patients with diabetes mellitus Methods Enzymol Warnick 129 101 1986 10.1016/0076-6879(86)29064-3 Enzymatic methods for quantification of lipoprotein lipids Clin Chem Warnick 36 1 15 1990 10.1093/clinchem/36.1.15 Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints Ann Clin Biochem Bouloux 22 Pt 2 194 1985 10.1177/000456328502200217 Methodological considerations in the determination of plasma cathecolamines by high-performance liquid chromatography with electrochemical detection Acta Haematol Clauss 17 4 237 1957 10.1159/000205234 Rapid physiological coagulation method for determination of fibrinogen J Physiol Born 162 67 1962 Quantitative investigation into the aggregation of blood platelets Singer 115 2000 10.1016/S0169-7161(00)18007-1 Handbook of Statistics. Volume 18: Bio-Environmental and Public Health Statistics Analysis of longitudinal data Neter 1996 Applied Linear Statistical Models Clin Exp Pharmacol Physiol Meaney 35 8 895 2008 10.1111/j.1440-1681.2008.04920.x Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study Am Heart J Stocker 153 3 445.e1 2007 10.1016/j.ahj.2006.11.005 A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes Zhong Nan Da Xue Xue Bao Yi Xue Ban Huang 31 3 367 2006 Effects of rosiglitazone on the IMTc and serum MMP-9 levels in newly diagnosed type 2 diabetic patients Heart Stakos 91 5 589 2005 10.1136/hrt.2003.027722 Long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance: double blind, prospective, randomized study Horm Metab Res Clark 28 9 445 1996 10.1055/s-2007-979835 The effect of glimepiride on pancreatic beta – cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non insulin. dependent diabetes mellitus Endocr J Inoguchi 47 6 763 2000 10.1507/endocrj.47.763 Chronic sulfonylurea treatment and hyperglycemia aggravate disproportionately elevated plasma proinsulin levels in patients with 2 diabetes J Clin Invest Reitman 117 5 1226 2007 10.1172/JCI32133 Pharmacogenetics of metformin response: a step in the path toward personalized medicine Am J Physiol Endocrinol Metab Bansal 295 4 E751 2008 10.1152/ajpendo.90295.2008 Insulin as a physiological modulator of glucagon secretion Diabetes Metab Grant 29 4 Pt 6S44 2003 Beneficial effects of metformin on haemostasis and vascular function in man J Lab Clin Med Wing 117 2 109 1991 Clearance of t-PA, PAI-1, and t-PA-PAI-1 complex in an isolated perfused rat liver system Metformin Use and Mortality Among Patients With Diabetes and Atherothrombosis. Arch Intern Med Roussel 170 21 1892 2010 For the Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators